COMPENSATION AND BENEFITS 15 15.3.2 SHARE WARRANTS OR SHARE WARRANTS FOR FOUNDERS GRANTED TO SENIOR EXECUTIVES AND DIRECTORS IN 2016 AND 2017 Table 4 (AMF definition) Name Grant Date Type of Grant Number Exercise Price Expiration Date of Ordinary Shares (€) Underlying Awards (#) Peter Goodfellow 07/26/2016 BSA(1) 7,000 8.080 07/25/2023 07/27/2017 BSA(1) 10,000 5.040 07/26/2024 Michael Wyzga 07/26/2016 BSA(1) 31,000 8.080 07/25/2023 07/27/2017 BSA(1) 15,000 5.040 07/26/2024 Simone Seiter 07/27/2017 BSA(1) 30,000 5.040 07/26/2024 Natalie Mount 07/27/2017 BSA(1) 30,000 5.040 07/26/2024 (1) BCE refers to share warrants for founders. BSA refers to share warrants. AGA refers to free shares. 15.3.3 SHARE WARRANTS OR SHARE WARRANTS FOR FOUNDERS EXERCISED BY SENIOR EXECUTIVES AND DIRECTORS IN 2016 AND 2017 Table 5 (AMF definition) Name Grant Date Number of Share Warrants Exercise Price and Share Warrants (€) for Founders Exercised Bernard Gilly 07/08/2013 594,496 (1) 0.025 Peter Goodfellow — — — Michael Wyzga — — — Simone Seiter — — — Natalie Mount — — — (1) All the coupons exercised were awarded before the grouping operations approved by the General Shareholders’ Meeting of August 17, 2015. Five exercised coupons entitled the holder to subscription of two new shares of nominal €0.025 value, therefore 237,798 new shares were issued. 15.3.4 FREE SHARES TO SENIOR EXECUTIVES AND DIRECTORS GRANTED IN 2016 AND 2017 Table 6 (AMF definition) Name Grant Date Number Value of shares Beginning End of Lock- Performance of Shares Granted according of Acquisition up Period Criteria to IFRS2 Period Bernard Gilly 07/26/2016 250,000 2,000,000 07/26/2017 (1) (2) (3) 07/27/2017 200,000 1,024,000 07/27/2018 (4) (5) (6) (1) If the performance criteria are not fulfilled by July 26, 2018 at the latest, the free shares granted will be canceled. (2) The lock-up period will end one (1) year after the end of the actual acquisition date. (3) The AGA 2016 granted to Key Managers, including Mr. Gilly, are subordinate to the achievement of the following performance criteria at the latest on July 26, 2018: • 50% of AGA 2016 were acquired at the completion of enrollment in RESCUE and REVERSE clinical trials on 07/27/2017; • 50% of AGA 2016 will be acquired at the enrollment of the first patient in a Phase I/I I clinical trial with GS030 in retinitis pigmentosa. (4) If the performance criteria are not fulfilled by July 26, 2019 at the latest, the free shares granted will be canceled. (5) The lock-up period will end one (1) year after the end of the actual acquisition date. (6) The AGA 2016 granted to Key Managers, including Mr. Gilly, are subordinate to the achievement of the following performance criteria at the latest on July 26, 2019: • 50% of AGA 2016 will be acquired at the receipt of the definitive results of the GS010 REVERSE clinical trials; • 50% of the AGA 2016 wil l be acquired at the completion of the renrol lement of 50% of the patients of the Phase I/I I clinical trials with GS030 in retinitis pigmentosa. 160– GENSIGHT BIOLOGICS – 2017 Registration Document